March / April 2023
Features
How multimodal imaging raises the bar for RRD repair
The potential of imaging biomarkers are emerging as useful outcome measures for future trials in rhegmatogenous retinal detachment.
The ocular side effects of emerging oncology meds
A review of how a variety of immunotherapy and targeted therapies for cancer can impact the retina and the rest of the eye.
Gene therapy delivery: Examining the evidence
A look at the benefits and drawbacks of the three dominant modalities in clinical trials.
Departments
Clinical Trial Closeup
A pill to head off worsening of DRSS
A Phase III trial is on deck for the oral Ref-1 inhibitor APX3330 after a Phase IIb study showed a potential benefit.
Conference Review
Update on mitochondrial stabilizers
Also from the Angiogenesis, Exudation, and Degeneration meeting, emerging treatments for nAMD and MacTel2, and a marker for anti-VEGF success in ROP.
Editor's Page
News
North of the Border
AI for the vitreoretinal surgeon
What’s in the pipeline, how it may change practice and what a chatbot has to say about it.
Retina Rounds
Sympathetic to the cause
A long-ago ocular trauma caused a sympathetic panuveitis in the fellow eye.
Social Media Specialist
The physician as social media vanguard
When social media, public education and human rights collide, what is the physician’s responsibility?
Surgical Pearl Video
Pearls for transretinal tumor biopsy
Steps to improve your chances of performing a successful transretinal tumor biopsy.
Current Issue
Continuing Medical Education
Additional Publications
Tuesday, October 8, 2024 | Learn More About Stargardt Disease
Location: Webinar
Time: 7:00 PM ET
Time: 7:00 PM ET
Speaker: Lejla Vajzovic, MD, FASRS
Sponsored by Alkeus Pharmaceuticals, Inc.
Earlier Treatment Can Matter for Macular Edema Following Retinal Vein Occlusion
Treating Chronic Inflammation Associated With Uveitis Affecting the Posterior Segment in a Retina Setting with YUTIQ
GA: Recognizing the Burden
Treatment of Proliferative Diabetic Retinopathy
Improving Wet AMD Outcomes With a Fellow Eye Strategy
